London, United Kingdom, 10/09/18 – Biotech and Money, the network for life science executive leaders, has become LSX - Life Science Executives. The rebranding reflects the evolution of the company and its vision for the future.
At its heart, our company is in the business of connecting senior life science executives with access to the capital, intelligence, innovation, and partners they need to grow their businesses. Our name change from Biotech and Money to LSX reflects our ability to deliver these opportunities to the wider life sciences community.
We aim to build on our long-standing mission to forge a fundamentally better way to facilitate investment, foster partnerships, and build relationships in healthcare, while also better representing the community we serve and our role in helping life science executives tackle the challenges they face.
We do this through our world-class conferences and events that break the mould with innovative formats, networking and business development opportunities, as well as through powerful thought leadership and media offerings.
Terry O’Dwyer, Co-CEO, said: “We are exceptionally excited to be LSX. This rebrand presents a fantastic opportunity to build on our current offering and work with the life sciences community to better facilitate partnerships, deals and investment.”
Access to venture capital and effective fundraising tactics are key to buil...Read More
Securing external investment is an undisputed priority for senior managemen...Read More
Understand how to commercialise via partnering in Europe and other markets ...Read More
The 2018 C-Suite Challenges in Life Sciences Survey from Biotech & Money/LS...Read More